Anthera Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 78   

Articles published

ANTH 1.84 0.00 (-0.27%)
price chart
Anthera Pharmaceuticals Inc.: Anthera and Patheon Sign Manufacturing ...
HAYWARD, Calif., Nov. 20, 2014 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) announced today it has signed a manufacturing and supply agreement with the Patheon´┐Ż division of DPx Holdings B.V.
PowerSecure International Inc. (POWR), Anthera Pharmaceuticals Inc (ANTH ...
Last Friday, Kevin Kotler's Broadfin Capital disclosed a marked increase (of almost 70%) in its exposure to Anthera Pharmaceuticals Inc (NASDAQ:ANTH). According to a Schedule 13G filed with the Securities and Exchange Commission, the fund now owns ...
Anthera Pharmaceuticals, Inc. ( Nasdaq:ANTH) reports Q3 EPS (31c ...
Anthera Pharmaceuticals, Inc. ( Nasdaq:ANTH) reports Q3 EPS (31c), consensus (39c). Anthera Pharmaceuticals (ANTH) reported its Q3 results, with net loss for the three months ended September 30, 2014 at $7.0 million, compared to $5.8 million for the ...
Anthera Pharmaceuticals (ANTH) Releases Quarterly Earnings Results  Mideast Time
Active Stocks: Johnson & Johnson (NYSE:JNJ), ON Semiconductor Corp ...  Gaining Green
Related articles »  
Anthera Pharmaceuticals Reports 2014 Third Quarter Financial Results and ...
HAYWARD, Calif., Nov. 14, 2014 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. ANTH, +0.56% today announced financial results and operational update for the third quarter ended September 30, 2014.
Related articles »  
4 Reasons To Buy Anthera Pharmaceuticals
Anthera Pharmaceutical has recently presented the results of the Phase IIb on their studies for the treatment of systemic lupus erythematosus.
Related articles »  
The 52-Week Low Club for Friday
Anthera Pharmaceuticals Inc. (NASDAQ: ANTH) dropped about 2.3% on Friday to a new 52-week low of $2.33. Share volume is about equal to the daily average of around 127,000.
Related articles »  
Anthera Pharmaceuticals, Inc. (ANTH) Posts Q1 Loss of 39c/Share
Additional information and publications from the CHABLIS-SC1 clinical study can be found at http://www.anthera.com/studies_chablis-sc1.
Anthera Pharmaceuticals Reports 2014 First Quarter Financial Results and ...  MarketWatch
Related articles »  
Anthera Pharmaceuticals Announces Update on Strategic Partnership ...
HAYWARD, Calif., Oct. 1, 2014 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) today confirmed it is engaged in potential partnership negotiations for blisibimod for both lupus and IgA nephropathy in territories outside the United States.
Related articles »  
Anthera Pharmaceuticals (ANTH) Posts Quarterly Earnings Results, Beats ...
Anthera Pharmaceuticals logo Anthera Pharmaceuticals (NASDAQ:ANTH) posted its quarterly earnings results on Friday. The company reported ($0.31) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.39) by $0.08, Analyst ...
Anthera Pharmaceuticals (ANTH) Jumps: Stock Rises 10.3%
Anthera Pharmaceuticals, Inc. (ANTH - Snapshot Report) was a big mover last session, as its shares rose over 10% on the day.